Sign In
Buy CSTL
$24.69
-0.795 (-3.12%)
At Close: Jul 24, 2026
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Wednesday, 28'th Feb 2024
The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
06:41pm, Wednesday, 28'th Feb 2024
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
Castle Biosciences to Present at Upcoming Investor Conferences
01:00pm, Wednesday, 08'th Nov 2023
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings
09:02pm, Thursday, 02'nd Nov 2023
Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics comp
Castle Biosciences to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 05'th Sep 2023
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced that Derek Maetzold and Frank Stokes will present a company overview at Baird's 2023 Global Healthc
Why Castle Biosciences Stock Is Jumping Today
11:17am, Thursday, 03'rd Aug 2023
Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook.
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings
08:58pm, Wednesday, 02'nd Aug 2023
While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key m
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
11:43am, Wednesday, 26'th Jul 2023
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
07:00am, Wednesday, 19'th Jul 2023
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Aug. 2, 2023.
Why Shares of Castle Biosciences Fell This Week
05:18pm, Thursday, 13'th Jul 2023
Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to inform cancer treatment choices.
Castle Biosciences stock soars on Medicare reversal; data presentation
03:24pm, Friday, 07'th Jul 2023
Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy that would have denied coverage of Castle's Decis
Why Castle Biosciences Stock Is Crushing It Today
12:16pm, Friday, 07'th Jul 2023
Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the regional Medicare administrative contractor.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data on DecisionDx®-SCC and DecisionDx®-Melanoma at AHNS' 11th International Conference on Head and Neck Cancer.
Why Shares of Castle Biosciences Plummeted on Monday
03:04pm, Monday, 05'th Jun 2023
A Medicare contractor proposed non-coverage of one of Castle's skin cancer tests. The company reiterated guidance.
Why Shares of Castle Biosciences Slumped This Week
05:04pm, Friday, 02'nd Jun 2023
Castle Biosciences' shares are down more than 3% this year. The company specializes in medical diagnostics to improve patient treatment plans.
